Last

In clinical trials, Libmeldy offered clear benefits to infantile and juvenile patients who hadn’t yet developed MLD symptoms; these patients were able to break down sulfatides at normal rates and showed typical patterns of motor development. The benefits of the therapy seem to last several years, but at this point “it is not yet clear whether it will persist life-long, and extended follow-up is needed,” the European Medicines Agency noted.